MX391165B - Inhibidores de pla2 secretados para usarse en el tratamiento inmediato de envenenamiento por himenópteros - Google Patents

Inhibidores de pla2 secretados para usarse en el tratamiento inmediato de envenenamiento por himenópteros

Info

Publication number
MX391165B
MX391165B MX2018013084A MX2018013084A MX391165B MX 391165 B MX391165 B MX 391165B MX 2018013084 A MX2018013084 A MX 2018013084A MX 2018013084 A MX2018013084 A MX 2018013084A MX 391165 B MX391165 B MX 391165B
Authority
MX
Mexico
Prior art keywords
hymenoptera
poisoning
pla2 inhibitors
immediate treatment
secreted pla2
Prior art date
Application number
MX2018013084A
Other languages
English (en)
Spanish (es)
Other versions
MX2018013084A (es
Inventor
Matthew R Lewin
Original Assignee
Ophirex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ophirex Inc filed Critical Ophirex Inc
Publication of MX2018013084A publication Critical patent/MX2018013084A/es
Publication of MX391165B publication Critical patent/MX391165B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/366Lactones having six-membered rings, e.g. delta-lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
MX2018013084A 2016-04-29 2017-05-01 Inhibidores de pla2 secretados para usarse en el tratamiento inmediato de envenenamiento por himenópteros MX391165B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662329611P 2016-04-29 2016-04-29
US201662340075P 2016-05-23 2016-05-23
US201662423693P 2016-11-17 2016-11-17
PCT/US2017/030436 WO2017190141A1 (en) 2016-04-29 2017-05-01 Pla2 and hmg-coa inhibitors for treatment of pathological conditions causing hemolysis, cerebral edema, and acute kidney injury

Publications (2)

Publication Number Publication Date
MX2018013084A MX2018013084A (es) 2019-03-06
MX391165B true MX391165B (es) 2025-03-21

Family

ID=60161200

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018013084A MX391165B (es) 2016-04-29 2017-05-01 Inhibidores de pla2 secretados para usarse en el tratamiento inmediato de envenenamiento por himenópteros
MX2022003739A MX2022003739A (es) 2016-04-29 2018-10-25 Inhibidores de pla2 secretados para usarse en el tratamiento inmediato de envenenamiento por himenopteros.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022003739A MX2022003739A (es) 2016-04-29 2018-10-25 Inhibidores de pla2 secretados para usarse en el tratamiento inmediato de envenenamiento por himenopteros.

Country Status (9)

Country Link
US (2) US12383531B2 (enExample)
EP (1) EP3448378B1 (enExample)
JP (2) JP7542935B2 (enExample)
KR (2) KR102723249B1 (enExample)
CN (2) CN109562098B (enExample)
AU (2) AU2017257185B8 (enExample)
IL (2) IL262620B2 (enExample)
MX (2) MX391165B (enExample)
WO (1) WO2017190141A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7542935B2 (ja) 2016-04-29 2024-09-02 オフィレックス インコーポレイテッド 溶血、脳浮腫および急性腎障害を引き起こす病態の治療のためのpla2およびhmg-coa阻害剤
WO2023086343A1 (en) * 2021-11-09 2023-05-19 Ophirex, Inc. Compositions and dosage forms for topical and transdermal delivery of actives and methods of use

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL84252A (en) 1987-10-23 1994-02-27 Yissum Res Dev Co Phospholipase inhibiting compositions
SI0675110T1 (en) * 1994-04-01 2002-12-31 Eli Lilly And Company 1H-Indole-3-glyoxylamide sPLA2 inhibitors
DE69716619T2 (de) * 1996-08-28 2003-06-26 The Procter & Gamble Company, Cincinnati Phosphinsäureamide als matrix metalloprotease inhibitoren
AUPP076797A0 (en) * 1997-12-05 1998-01-08 Active (Pla) R&D Pty Ltd Phospholipase inhibitor
GB2365769A (en) * 2000-08-18 2002-02-27 Secr Defence Skin preparations containing silicon
US8106019B2 (en) * 2002-11-15 2012-01-31 Philadelphia Health & Education Corporation CHEC-7 a novel sPLA2 inhibitor
AU2004270261B2 (en) * 2003-09-09 2008-12-04 University Of Florida Research Foundation, Inc. Polyamine-metal chelator conjugates
FR2873293B1 (fr) 2004-07-21 2006-11-17 Cerep Sa Utilisation d'un acide gras pour la preparation d'une composition topique destinee a l'apaisement des reactions inflammatoires dues aux piqures d'hymenopteres a venin
JP2008538586A (ja) 2005-04-21 2008-10-30 グレン エー. ゴールドスタイン, 酸化ストレスに関連する疾患および病気の処置のためのn−アセチルシステインアミド(nacアミド)
US20100204249A1 (en) * 2009-01-08 2010-08-12 Colin Hislop Secretory phospholipase a2 (spla2) inhibitor and niacin drug compositions and methods for treating cardiovascular disease and dyslipidemia
US20110269786A1 (en) * 2010-04-30 2011-11-03 Colin Hislop Treatment of major adverse cardiac events and acute coronary syndrome in diabetic patients using secretory phospholipase a2 (spla2) inhibitor or spla2 inhibitor combination therapies
AU2013312240A1 (en) * 2012-09-10 2015-03-19 Ophirex Inc. Administration of acetylcholinesterase inhibitors to mitigate neurotoxin-induced paralysis and residual neuromuscular blockade
US20140087003A1 (en) * 2012-09-21 2014-03-27 Ignacio Cisneros Method for treating venomous bites and stings
MA40998A (fr) 2014-11-21 2017-09-26 Ophirex Inc Thérapies contre une envenimation, ainsi que compositions, systèmes et kits pharmaceutiques associés
US10786483B2 (en) * 2016-03-04 2020-09-29 Hk Pharma Tumescent contravenom drug delivery
JP7542935B2 (ja) 2016-04-29 2024-09-02 オフィレックス インコーポレイテッド 溶血、脳浮腫および急性腎障害を引き起こす病態の治療のためのpla2およびhmg-coa阻害剤

Also Published As

Publication number Publication date
MX2018013084A (es) 2019-03-06
CN109562098A (zh) 2019-04-02
US20250120949A1 (en) 2025-04-17
JP2022177020A (ja) 2022-11-30
JP7542935B2 (ja) 2024-09-02
MX2022003739A (es) 2022-05-02
AU2017257185B9 (en) 2023-07-06
AU2023233187A1 (en) 2023-10-12
KR20230049762A (ko) 2023-04-13
CN116585306A (zh) 2023-08-15
US12383531B2 (en) 2025-08-12
WO2017190141A1 (en) 2017-11-02
AU2017257185A1 (en) 2018-11-22
KR102723249B1 (ko) 2024-10-28
JP2019514935A (ja) 2019-06-06
EP3448378C0 (en) 2024-04-17
EP3448378A1 (en) 2019-03-06
IL262620A (en) 2018-12-31
EP3448378B1 (en) 2024-04-17
CN109562098B (zh) 2023-04-21
AU2017257185B8 (en) 2023-07-06
IL262620B1 (en) 2023-10-01
IL307232B1 (en) 2025-12-01
BR112018072162A2 (pt) 2019-02-12
IL262620B2 (en) 2024-02-01
CA3022013A1 (en) 2017-11-02
CN116585306B (zh) 2025-06-20
US20210220332A1 (en) 2021-07-22
IL307232A (en) 2023-11-01
EP3448378A4 (en) 2020-04-08
AU2017257185B2 (en) 2023-06-22
KR20190005898A (ko) 2019-01-16

Similar Documents

Publication Publication Date Title
DOP2019000180A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
EA201892625A1 (ru) КОМБИНИРОВАННАЯ ТЕРАПИЯ С ПРИМЕНЕНИЕМ ИНГИБИТОРА АЦЕТИЛ-КоА-КАРБОКСИЛАЗЫ (ACC) ДЛЯ ЛЕЧЕНИЯ НЕАЛКОГОЛЬНОЙ ЖИРОВОЙ БОЛЕЗНИ ПЕЧЕНИ
MX2019007586A (es) Composiciones que comprenden tacrolimus para el tratamiento de enfermedades inflamatorias intraoculares.
PT4122464T (pt) Combinações terapêuticas para o tratamento de doenças do fígado
EA201890006A1 (ru) Применение экзосом для лечения болезни
EP3558237C0 (en) SYSTEM FOR TARGETED APPLICATION OF TOPICAL AGENTS TO AN ISOLATED BODY PART
EP3429605A4 (en) THERAPEUTIC FOR THE TREATMENT OF DISEASES INCLUDING THE CENTRAL NERVOUS SYSTEM
EA201790575A1 (ru) Триазолопиразиноны в качестве ингибиторов pde1
PT3481846T (pt) 24-hidroxiesteroides 11-substituídos para utilização no tratamento de afeções relacionadas com nmda
EA201792157A1 (ru) Имидазопиразиноны в качестве ингибиторов pde1
MX2019015311A (es) Composiciones de ésteres de ácido cannabidiólico y usos de las mismas.
BR112015027399A2 (pt) ANTICORPOS ANTI-IGF-1R COM LIGAÇÃO DE FcRn ABOLIDA E SEU USO NO TRATAMENTO DE ENFERMIDADES VASCULARES OCULARES
MX395231B (es) Compuestos eficaces en el tratamiento de la hepatotoxicidad y enfermedades de hígado graso, y uso de los mismos.
MX385762B (es) Métodos para el control transcripcional objetivo en regiones del super mejorador.
IL280664A (en) 2-arylbenzimidazoles as ppargc1a activators for treating neurodegenerative diseases
EA201692402A1 (ru) Лекарственные формы для местного применения и их использование
EA201792610A1 (ru) Способ лечения неврологического заболевания
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
EA201892265A1 (ru) Способы лечения офтальмологических заболеваний
WO2016029136A8 (en) 3-amidobenzamides and uses thereof for increasing cellular levels of a3g
MX2015011775A (es) Uso de levocetirizina y montelukast en el tratamiento de anafilaxis.
EA201691108A1 (ru) Хиназолин-thf-амины в качестве ингибиторов pde1
IL262801A (en) 2-anilinopyrimidine derivatives as therapeutic agents for treatment of brain cancers
EA201691335A1 (ru) Гексагидрофуропирролы в качестве ингибиторов pde1
MX379715B (es) 1-arilnaftiridin-3-carboxamidas 7-sustituidas y su uso.